Table 4:

LD patients identified at baseline by the six individual proteins in the verification cohort.

Protein	APOA4	C9	CRP	CST6	PGLYRP2	S100A9
Peptide	LGPHAGDVEGHLSFLEK	LSPIYNLVPVK	ESDTSYVSLK	AQSQLVAGIK	EFTEAFLGCPAIHPR	LGHPDTLNQGEFK
P value (t-test)	2.5E-05**	3.0E-03**	5.0E-04**	4.0E-02*	7.0E-03*	4.0E-03**
FC cutoff	< 0.33	> 1.6	> 4.5	< 0.60	< 0.35	> 2.2
Partial AUC at cutoff
sensitivity	40.0%	41.2%	64.7%	24.3%	22.9%	27.0%
specificity	92.5%	92.5%	97.5%	90.0%	97.5%	92.5%
# of patients detected at cutoff
Lyme (n=30)	8 (26.7%)	12 (40.0%)	22 (73.3%)	8 (26.7%)	6 (20.0%)	11 (36.7%)
Average FC to controls
Sero −	0.42 ± 0.29	1.61 ± 0.98	24.47 ± 36.86	0.81 ± 0.37	0.78 ± 0.31	1.69 ± 0.95
Sero +	0.57 ± 0.47	1.59 ± 0.73	14.00 ± 15.74	0.83 ± 0.4	0.81 ± 0.38	1.76 ± 1.36
Healthy control	1 ± 0.6	1 ± 0.43	1 ± 1.17	1 ± 0.32	1 ± 0.41	1 ± 0.75
t-test P value
Sero − vs. Control	1.4E-05**	3.2E-02*	2.2E-02*	7.8E-02*	4.3E-02*	1.6E-02*
Sero + vs. Control	9.2E-03*	1.1E-02*	4.7E-03**	1.4E-01	1.1E-01	5.4E-02
Sero + vs. Sero −	3.3E-01	9.4E-01	3.1E-01	8.7E-01	7.9E-01	8.7E-01

^*cutoff value is the fold change to average of healthy controls in the same sample set.

Sero−: LD patient group with negative first-tier serology test (EIA) at diagnosis

Sero+: LD patient group with positive serology test at diagnosis.

^*:t-test P < 0.05

^**:P < 0.005.